<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01158547</url>
  </required_header>
  <id_info>
    <org_study_id>CLR3001</org_study_id>
    <nct_id>NCT01158547</nct_id>
  </id_info>
  <brief_title>Efficacy Study of CLR3001 in Depression</brief_title>
  <official_title>A Pilot Placebo Controlled, Double-Blind, Randomized Parallel Group Study to Evaluate the Efficacy of Treatment With CLR3001 in Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clera Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clera Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the ability of CLR3001 to reverse depressive symptoms
      relatively quickly in adult patients with major depressive disorder (MDD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CLR3001 is thought to work by helping the body's natural responses overcome depression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy using Hamilton Rating Scale for Depression</measure>
    <time_frame>Weeks 2 to 7</time_frame>
  </primary_outcome>
  <enrollment type="Actual">86</enrollment>
  <condition>Depression</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Community sample
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female out-subjects 18-65 years.

          -  Single episode or recurrent MDD (to a maximum of 5 prior episodes).

          -  No current therapy for depression as per washout instructions.

          -  Able to provide written informed consent.

          -  Meet criteria for MDD with current MDE through MINI questionnaire.

          -  Meet criteria for MDD with current MDE, as defined by DSM-IV TR.

          -  HAMD-17 score ≥ 14 at screening (visit 1) and baseline (Visit 2; Randomization).

          -  Able to understand and complete questionnaires, and communicate with the investigator
             and study coordinator.

          -  Judged to be reliable to keep all appointments and procedures required by the
             protocol.

          -  Female subjects of childbearing potential (who are not at least 2 years postmenopausal
             or surgically sterile or totally abstinent) must be using a reliable, medically
             acceptable form of contraception and must agree to continue such use throughout the
             duration of the study. Reliable forms of contraception include oral, implanted,
             transdermal or injected contraceptives, intrauterine devices, and adequate double
             barrier methods including use of spermicide. Partner's vasectomy is also an acceptable
             contraceptive regimen.

        Exclusion Criteria:

          -  Investigators and immediate family members.

          -  Treatment within the last 90 days with a drug that had not received regulatory
             approval at the time of study entry.

          -  Persons who had previously withdrawn from this study or previous study investigating
             CLR3001.

          -  A primary diagnosis of Panic Disorder, Social Anxiety Disorder, Obsessive-Compulsive
             Disorder within the past year.

          -  The presence of an Axis II disorder, which, in the opinion of the investigator, would
             interfere with compliance in the study.

          -  History of active substance dependence within the last half-year, excluding nicotine
             and coffee, or active substance abuse that may interfere with the outcome of the
             study.

          -  Acute suicidal ideation or risk, ≥3 on HAMD-17 suicide item.

          -  Fall in HAMD-17 score greater than 20% between Visit 1 and Visit 2.

          -  Serious concomitant diseases such as cancer, serious metabolic (e.g. Insulin dependent
             diabetes), renal, cardiac, thyroid, immunological, neurological or other significant
             disease or laboratory abnormality (hematology, blood chemistry, ECG), or treatment for
             medical conditions which may interact with CLR3001.

          -  Women who are pregnant or breast-feeding, or men or women who plan to

          -  Infirmities or living in an area limiting participation in the study or compliance
             with study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sidney Kennedy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2010</study_first_submitted>
  <study_first_submitted_qc>July 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2010</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

